Viva Biotech provides one-stop services ranging from early-stage structure-based drug R&D to commercial manufacturing for global biopharmaceutical innovators. Established in 2008, Viva Biotech offers drug discovery expertise, integrating dedicated experts, cutting-edge technology platforms, and state-of-the-art equipment.

Viva Biotech

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

Totient

Temasek Holdings

Danming Fund

Honghui Fund

Beida Biomedical Industry Fund

Viva Ventures Biotech Fund

Ming Bioventures

Xiamen Changrong Investment Management

Yingqi Investment

JMCR Partners

Viva Biotech 

At Viva Biotech, we believe in #innovation. That's why our newly finished headquarters, with 40,000 square meters, features new, state-of-the-art facilities and laboratories. We strive to be the best partner in your #drugdiscovery, development, and production processes.

Are you curious about protein structure services at Viva Biotech? At Viva Biotech, experienced experts collaborate to provide comprehensive discovery biology services and expedite drug discovery.

Delve into the details: https://lnkd.in/gZmcRJac

#proteinstructure #cro #cdmo #sbdd #drugdiscoveryservices #drugdevelopment

We are honored that our subsidiary, Langhua Pharmaceutical, has received the API Development & Innovation Award at the CPHI China 2024. This recognition highlights Viva Biotech’s excellence in CDMO services. 

Learn more: https://lnkd.in/gnApkmCC

#CPHIChina #cdmo #API #vivabiotech #langhuapharmaceutical #PharmaInnovation #cro

Are you working with PROTACs? 

Elevate your drug discovery with Viva Biotech’s one-stop PROTAC services. Click on the image to explore our high-quality, efficient, and reliable support.

📢 Don't miss our upcoming PROTAC webinar! Register now to be part of this exciting event: https://lnkd.in/eAMH24CM

#protac #protacs #medchem #proteindegradation #undruggabletargets #cro #cdmo #vivabiotech #drugdiscovery #drugdevelopment

Join us for an enlightening webinar, this session will delve into cutting-edge strategies in PROTACs. Hear from leading experts Michael R.，David Taddei, Jean-Marc Garnier as they unveil their insights into Linkerology, case studies in PROTAC development, and structure-guided optimization strategies. 

Mark your calendars, the date is set! Register now and be part of the revolution in drug discovery!

Here is the registration link: https://lnkd.in/eAMH24CM

#PROTAC #PROTACs #medchem #proteindegradationresearch #proteindegradationstrategy #proteindegradation #molecularglues #PROTACLinkers #compchem #drugdevelopment  #drugdiscovery #cro #cdmo #BiotechInnovation

We're delighted to share that our V-DEL platform poster presentation at SABPA the 8th Annual Frontiers in Therapeutics and Diagnostics (FTD) was awarded the “Excellence Award” last month! This recognition marks the first time we've showcased our DEL platform poster at a conference and underscores our commitment to innovative technology. Additionally, our team had the pleasure of hosting a Lunch and Learn workshop at the FTD Forum in San Diego. Our experts, Yinghong Gao, highlighted our cutting-edge V-DEL platform as part of our comprehensive, one-stop drug discovery platforms. Meanwhile, Jianguo Ma showcased Zhejiang Langhua Pharmaceutical Co., Ltd.'s CDMO services, capturing significant attention.
 
Curious to learn more about our hit discovery platforms? Reach out to us at marketing@vivabiotech.com for further details. At Viva Biotech, we're dedicated to accelerating your drug discovery journey, from SBDD to commercial manufacturing.

#cro #cdmo #del #drugdiscovery #sbdd #biotech #FTD #sabpa #drugdevelopment #bioresearch #biopharmaceuticals

Metric
Company Name	Viva Biotech
Symbol
MSH ID	COM:VIVABIOTECH
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Pharmaceutical Services
Country	HK
Stage
Employee Count	121
Website	vivabiotech.com
LinkedIn	vivabiotech
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

VIVA

COM:VIVABIOTECH

Viva Biotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue